EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer

Eduardo Pons-Fuster, Celia Maria Gonzalez-Ponce, Silverio Ros-Martinez, Juan José Fernández-Ávila, María Sacramento Díaz-Carrasco, Alberto Espuny-Miró

International Journal of Clinical Pharmacy · 2025-12 · 47 (6) · 1701-1709

DOI: 10.1007/s11096-025-01920-4 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Clinical Pharmacy, online erschienen am 06.05.2025. Verfasst von Eduardo Pons-Fuster und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy and Therapeutics Research Group, Servicio de Farmacia Hospitalaria, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Ctr…. Hauptthemen laut MEDLINE: Thiohydantoins, Prostatic Neoplasms, Androgen Antagonists, Androstenes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad de Murcia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic hormone-sensitive prostate cancer (mHSPC) is an aggressive disease with a poor prognosis. Current treatment guidelines recommend combining androgen receptor axis-targeted therapies (ARATs) with androgen deprivation therapy (ADT) for mHSPC. While individual ARATs have shown success, few studies directly compare their effects.

Aim

To compare the safety and clinical outcomes of abiraterone acetate (abiraterone) and apalutamide in chemotherapy-naïve mHSPC patients, focusing on prostate-specific antigen (PSA) kinetics, safety, and survival outcomes.

Method

A retrospective, single-centre study included 107 chemotherapy-naïve mHSPC patients treated with abiraterone or apalutamide plus ADT. PSA levels were measured at baseline and during treatment. Primary outcomes were PSA progression-free survival (PSA-PFS) and overall survival (OS). Adverse events were recorded. Inverse probability treatment weighting adjusted baseline differences.

Results

Median PSA-PFS significantly favoured apalutamide (log-rank p = 0.015). Achieving PSA ≤ 0.02 ng/mL was strongly associated with delayed progression (HR 0.07, 95% CI 0.02–0.28; p < 0.001). OS did not differ significantly between groups ( p = 0.504). Apalutamide achieved lower median nadir PSA (0.02 ng/mL vs. 0.23 ng/mL, p < 0.001) and shorter mean time to nadir (4.5 vs. 7.2 months, p = 0.001), with more patients reaching ultralow PSA levels (≤ 0.02 ng/mL) during follow-up. Adverse events occurred more frequently with apalutamide (71.2% vs. 46.5%, p = 0.015), with fatigue and rash being the most common.

Conclusion

Apalutamide demonstrated deeper and more sustained PSA reductions, translating into delayed disease progression compared to abiraterone. Both treatments were generally well tolerated, though adverse events were more prevalent with apalutamide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiohydantoinsProstatic NeoplasmsAndrogen AntagonistsAndrostenesAntineoplastic Combined Chemotherapy ProtocolsHumansMaleRetrospective StudiesAgedMiddle AgedTreatment OutcomeAged, 80 and overProstate-Specific AntigenProgression-Free SurvivalAbiraterone Acetate

Stichwörter der Autor:innen

AbirateroneAntineoplastic agentsApalutamideProstate-specific antigenProstatic neoplasms

Substanzen

apalutamideThiohydantoinsabirateroneAndrogen AntagonistsProstate-Specific AntigenAndrostenesAbiraterone Acetate

Autor:innen und Institutionen

  • Clinical Pharmacy and Therapeutics Research Group, Servicio de Farmacia Hospitalaria, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Ctra. Madrid-Cartagena, s/n, 30120, El Palmar, Spain. eduardo.p.f@um.es.
  • Clinical Pharmacy and Therapeutics Research Group, Servicio de Farmacia Hospitalaria, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Ctra. Madrid-Cartagena, s/n, 30120, El Palmar, Spain.
  • Clinical and Translational Oncology Research Group, Clinical Oncology Unit, Virgen de la Arrixaca University Clinical Hospital (HCUVA), El Palmar, Spain.

Förderung

  • Universidad de Murcia

Zitieren

APA

Pons-Fuster, E., Gonzalez-Ponce, C. M., Ros-Martinez, S., Fernández-Ávila, J. J., Díaz-Carrasco, M. S., & Espuny-Miró, A. (2025). Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. International Journal of Clinical Pharmacy, 47(6), 1701-1709. https://doi.org/10.1007/s11096-025-01920-4

Vancouver

Pons-Fuster E, Gonzalez-Ponce CM, Ros-Martinez S, Fernández-Ávila JJ, Díaz-Carrasco MS, Espuny-Miró A. Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. International Journal of Clinical Pharmacy. 2025;47(6):1701-1709. doi:10.1007/s11096-025-01920-4

BibTeX
@article{PonsFuster2025,
  author = {Pons-Fuster, Eduardo and Gonzalez-Ponce, Celia Maria and Ros-Martinez, Silverio and Fernández-Ávila, Juan José and Díaz-Carrasco, María Sacramento and Espuny-Miró, Alberto},
  title = {Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer},
  journal = {International Journal of Clinical Pharmacy},
  year = {2025},
  volume = {47},
  number = {6},
  pages = {1701--1709},
  doi = {10.1007/s11096-025-01920-4}
}
Kostenlos starten →